AI English summary of an SEC filing — figures as filed
Biogen BIIBThe company said global TECFIDERA revenue fell $1,443.9 million from 2023 to 2022, or 29.9%, to $1,012.5 million from $431.4 million, citing lower demand from multiple generic entrants in North America, Brazil and certain E.U. countries.
Key points
AI summaryThe company said global TECFIDERA revenue fell $1,443.9 million from 2023 to 2022, or 29.9%, to $1,012.5 million from $431.4 million, citing lower demand from multiple generic entrants in North America, Brazil and certain E.U. countries.
Biogen said it recorded a fair value step-up adjustment of about $1.3 billion on SKYCLARYS inventory from its acquisition of Reata in September 2023, and that the amortization on inventory sold in Q4 2023 was about $31.5 million. It said it began recognizing U.S. SKYCLARYS revenue of $55.9 million in Q4.
In connection with the Reata acquisition, the company said it drew $1.0 billion on the closing date from a $1.5 billion term loan credit agreement, and repaid $350.0 million of the 364-day tranche in Q4. It said $650.0 million remained outstanding under the term loan as of December 31, 2023.
The company said it made no share repurchases under its 2020 Share Repurchase Program (up to $5.0 billion) in 2023, and that about $2.1 billion remained available under the program as of December 31, 2023.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $9.8B
- Net income
- $1.2B
- EPS
- $7.97
- Operating cash flow
- $1.5B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
TECFIDERA Revenue Decline and Company Explanation
The company said global TECFIDERA revenue fell $1,443.9 million from 2023 to 2022, or 29.9%, to $1,012.5 million from $431.4 million, citing lower demand from multiple generic entrants in North America, Brazil and certain E.U. countries.
Source · Based on the MD&A text of the filing
Reata acquisition and SKYCLARYS inventory step-up
Biogen said it recorded a fair value step-up adjustment of about $1.3 billion on SKYCLARYS inventory from its acquisition of Reata in September 2023, and that the amortization on inventory sold in Q4 2023 was about $31.5 million. It said it began recognizing U.S. SKYCLARYS revenue of $55.9 million in Q4.
Source · Based on the MD&A text of the filing
2023 Term Loan Draws and Year-End Balance
In connection with the Reata acquisition, the company said it drew $1.0 billion on the closing date from a $1.5 billion term loan credit agreement, and repaid $350.0 million of the 364-day tranche in Q4. It said $650.0 million remained outstanding under the term loan as of December 31, 2023.
Source · Based on the MD&A text of the filing
Share Repurchase Activity and Remaining Authorization
The company said it made no share repurchases under its 2020 Share Repurchase Program (up to $5.0 billion) in 2023, and that about $2.1 billion remained available under the program as of December 31, 2023.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…